{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:03:58Z","timestamp":1748923438608,"version":"3.41.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To identify diabetic maculopathy features from photographic screening that are predictive of treatment on referral to a tertiary care centre.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Retrospective review of participants who underwent screening by Singapore Integrated Diabetic Retinopathy Programme from 2015 to 2019. Participants underwent visual acuity (VA) test and non-stereoscopic retinal photographs. Maculopathy features include haemorrhages, microaneurysm and hard exudates (HE), stratified by inner and outer zone (1 and 1-2 disc diameter from fovea respectively) and VA of 6\/12. Diabetic macular oedema (DMO) treatment was defined as intravitreal injection or macular photocoagulation up to 540 days from point of referral.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>16,712 patients screened had referable eye disease. Out of 3518 maculopathy suspects, 281 (8.0%) received DMO treatment within 540 days. Those treated for DMO had shorter duration of diabetes (6.90 vs. 9.13 years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), higher total cholesterol (4.65\u2009\u00b1\u20091.20 vs. 4.36\u2009\u00b1\u20091.13\u2009mmol\/L, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and LDL cholesterol (2.59\u2009\u00b1\u20091.05 vs. 2.37\u2009\u00b1\u20090.93\u2009mmol\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) than those without treatment. High-risk features, including inner zone haemorrhages with VA\u2009\u2264\u20096\/12 (HR 12.0, 95% CI: 5.5\u201325.9) and inner zone hard exudates (HR 7.4, 95% CI: 3.4\u201315.8), significantly increased the likelihood of requiring DMO treatment compared to low-risk features. Higher body mass index is protective of DMO treatment in mild non-proliferative diabetic retinopathy (HR 0.84, 95% CI: 0.73\u20130.97).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Haemorrhages, microaneurysms and HE within inner zone are important photographic features predictive of DMO treatment. VA is an important stratification for screening especially in patients with only visible haemorrhages.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41433-025-03725-1","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T21:53:42Z","timestamp":1740779622000},"page":"1710-1716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting the need for diabetic macular oedema treatment from photographic screening in the Singapore Integrated Diabetic Retinopathy Programme (SiDRP)"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-0468","authenticated-orcid":false,"given":"Stanley S. J.","family":"Poh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin Y. C.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose Ann","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian Xin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haslina","family":"Hamzah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serene S. C.","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngiap Chuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-1264","authenticated-orcid":false,"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5383-7136","authenticated-orcid":false,"given":"Gavin S. W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"3725_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124\u201336.","journal-title":"Lancet"},{"key":"3725_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10654-019-00560-z","volume":"35","author":"JQ Li","year":"2020","unstructured":"Li JQ, Welchowski T, Schmid M, Letow J, Wolpers C, Pascual-Camps I, et al. Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35:11\u201323.","journal-title":"Eur J Epidemiol"},{"key":"3725_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ophtha.2017.10.026","volume":"125","author":"GS Tan","year":"2018","unstructured":"Tan GS, Gan A, Sabanayagam C, Tham YC, Neelam K, Mitchell P, et al. Ethnic differences in the prevalence and risk factors of diabetic retinopathy. Ophthalmology. 2018;125:529\u201336.","journal-title":"Ophthalmology"},{"key":"3725_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ophtha.2014.08.047","volume":"122","author":"MJ Elman","year":"2015","unstructured":"Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375\u201381.","journal-title":"Ophthalmology"},{"key":"3725_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789\u2013801.","journal-title":"Ophthalmology"},{"key":"3725_CR6","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials. Ophthalmology. 2013;120:2013\u201322.","journal-title":"Ophthalmology"},{"key":"3725_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ophtha.2013.11.041","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121:1045\u201353.","journal-title":"Ophthalmology"},{"key":"3725_CR8","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","volume":"110","author":"CP Wilkinson","year":"2003","unstructured":"Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677\u201382.","journal-title":"Ophthalmology"},{"key":"3725_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00592-017-0974-1","volume":"54","author":"PH Scanlon","year":"2017","unstructured":"Scanlon PH. The English National Screening Programme for diabetic retinopathy 2003\u20132016. Acta Diabetol. 2017;54:515\u201325.","journal-title":"Acta Diabetol"},{"key":"3725_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00592-021-01687-w","volume":"58","author":"PeterH Scanlon","year":"2021","unstructured":"Scanlon PeterH. The contribution of the English NHS Diabetic Eye Screening Programme to reductions in diabetes-related blindness, comparisons within Europe, and future challenges. Acta Diabetol. 2021;58:521\u201330.","journal-title":"Acta Diabetol"},{"key":"3725_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/bjophthalmol-2020-317508","volume":"106","author":"R Pandey","year":"2022","unstructured":"Pandey R, Morgan MM, Murphy C, Kavanagh H, Acheson R, Cahill M, et al. Irish National Diabetic RetinaScreen Programme: report on five rounds of retinopathy screening and screen-positive referrals. (INDEAR study report no. 1). Br J Ophthalmol. 2022;106:409\u201314.","journal-title":"Br J Ophthalmol"},{"key":"3725_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1136\/bjophthalmol-2013-303948","volume":"98","author":"HC Looker","year":"2014","unstructured":"Looker HC, Nyangoma SO, Cromie DT, Olson JA, Leese GP, Black MW, et al. Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. Br J Ophthalmol. 2014;98:790\u20135.","journal-title":"Br J Ophthalmol"},{"key":"3725_CR13","unstructured":"GOV.UK [Internet]. [cited 2024 May 25]. Diabetic eye screening: OCT in surveillance pathway. Available from: https:\/\/www.gov.uk\/government\/publications\/diabetic-eye-screening-optical-coherence-tomography-in-surveillance\/diabetic-eye-screening-oct-in-surveillance-pathway"},{"key":"3725_CR14","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"321","author":"CW Baker","year":"2019","unstructured":"Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. Effect of initial management with aflibercept vs. laser photocoagulation vs. observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321:1880.","journal-title":"JAMA"},{"key":"3725_CR15","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/S2589-7500(20)30060-1","volume":"2","author":"Y Xie","year":"2020","unstructured":"Xie Y, Nguyen QD, Hamzah H, Lim G, Bellemo V, Gunasekeran DV, et al. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. Lancet Digit Health. 2020;2:e240\u20139.","journal-title":"Lancet Digit Health"},{"key":"3725_CR16","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.ophtha.2016.08.021","volume":"123","author":"HV Nguyen","year":"2016","unstructured":"Nguyen HV, Tan GSW, Tapp RJ, Mital S, Ting DSW, Wong HT, et al. Cost-effectiveness of a national telemedicine diabetic retinopathy screening program in Singapore. Ophthalmology. 2016;123:2571\u201380.","journal-title":"Ophthalmology"},{"key":"3725_CR17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","volume":"98","author":"ETDRS","year":"1991","unstructured":"ETDRS. Early photocoagulation for diabetic retinopathy. Ophthalmology. 1991;98:766\u201385.","journal-title":"Ophthalmology"},{"key":"3725_CR18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on diabetic eye care. Ophthalmology. 2018;125:1608\u201322.","journal-title":"Ophthalmology"},{"key":"3725_CR19","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/bjophthalmol-2013-304338","volume":"98","author":"G Prescott","year":"2014","unstructured":"Prescott G, Sharp P, Goatman K, Scotland G, Fleming A, Philip S, et al. Improving the cost-effectiveness of photographic screening for diabetic macular oedema: a prospective, multi-centre, UK study. Br J Ophthalmol. 2014;98:1042\u20139.","journal-title":"Br J Ophthalmol"},{"key":"3725_CR20","first-page":"356","volume":"23","author":"RL Wong","year":"2017","unstructured":"Wong RL, Tsang CW, Wong DS, McGhee S, Lam CH, Lian J, et al. Are we making good use of our public resources? The false-positive rate of screening by fundus photography for diabetic macular oedema. Hong Kong Med J Xianggang Yi Xue Za Zhi. 2017;23:356\u201364.","journal-title":"Hong Kong Med J Xianggang Yi Xue Za Zhi"},{"key":"3725_CR21","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.2337\/diabetes.53.11.2883","volume":"53","author":"B Miljanovic","year":"2004","unstructured":"Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A Prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes. 2004;53:2883\u201392.","journal-title":"Diabetes"},{"key":"3725_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.diabres.2011.07.004","volume":"94","author":"P Romero-Aroca","year":"2011","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Fernandez-Ballart J, Plana-Gil N, Soler-Lluis N, Mendez-Marin I, et al. Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes. Diabetes Res Clin Pract. 2011;94:126\u201332.","journal-title":"Diabetes Res Clin Pract"},{"key":"3725_CR23","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.ophtha.2015.05.011","volume":"122","author":"R Das","year":"2015","unstructured":"Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and Diabetic Macular Edema. Ophthalmology. 2015;122:1820\u20137.","journal-title":"Ophthalmology"},{"key":"3725_CR24","doi-asserted-by":"publisher","first-page":"e0180252","DOI":"10.1371\/journal.pone.0180252","volume":"12","author":"EK Fenwick","year":"2017","unstructured":"Fenwick EK, Xie J, Man REK, Sabanayagam C, Lim L, Rees G, et al. Combined poor diabetes control indicators are associated with higher risks of diabetic retinopathy and macular edema than poor glycemic control alone. PLoS ONE. 2017;12:e0180252.","journal-title":"PLoS ONE"},{"key":"3725_CR25","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1097\/IAE.0000000000003167","volume":"41","author":"D Lent-Schochet","year":"2021","unstructured":"Lent-Schochet D, Lo T, Luu KY, Tran S, Wilson MD, Moshiri A, et al. Natural history and predictors of vision loss in eyes with diabetic macular edema and good initial visual acuity. Retina Phila Pa. 2021;41:2132\u20139.","journal-title":"Retina Phila Pa"},{"key":"3725_CR26","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet Lond Engl. 1998;352:837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"3725_CR27","doi-asserted-by":"crossref","unstructured":"Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994;125:177\u201388.","DOI":"10.1016\/S0022-3476(94)70190-3"},{"key":"3725_CR28","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/dme.14278","volume":"37","author":"JJ Smith","year":"2020","unstructured":"Smith JJ, Wright DM, Scanlon P, Lois N. Risk factors associated with progression to referable retinopathy: a type 2 diabetes mellitus cohort study in the Republic of Ireland. Diabet Med. 2020;37:1000\u20137.","journal-title":"Diabet Med"},{"key":"3725_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2147\/DMSO.S246032","volume":"13","author":"YH Li","year":"2020","unstructured":"Li YH, Sheu WHH, Lee IT. Influence of Diabetic Retinopathy on the Relationship Between Body Mass Index and Mortality in Patients with Poorly Controlled Type 2 Diabetes. Diabetes Metab Syndr Obes Targets Ther. 2020;13:907.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"3725_CR30","doi-asserted-by":"publisher","first-page":"e056332","DOI":"10.1136\/bmjopen-2021-056332","volume":"12","author":"W Li","year":"2022","unstructured":"Li W, Gong X, Wang W, Xiong K, Meng J, Li Y, et al. Association of different kinds of obesity with diabetic retinopathy in patients with type 2 diabetes. BMJ Open. 2022;12:e056332.","journal-title":"BMJ Open"},{"key":"3725_CR31","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1038\/s41366-021-00829-y","volume":"45","author":"C Ng Yin Ling","year":"2021","unstructured":"Ng Yin Ling C, Lim SC, Jonas JB, Sabanayagam C. Obesity and risk of age-related eye diseases: a systematic review of prospective population-based studies. Int J Obes. 2021;45:1863\u201385.","journal-title":"Int J Obes"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03725-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:23:53Z","timestamp":1748867033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03725-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3725"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03725-1","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}